AEHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aehr Test Systems (AEHR) has shown strong momentum due to a record $41 million production order, but its overbought technical indicators and declining financial performance suggest caution for a long-term beginner investor. Given the investor's preference for long-term stability and the lack of Intellectia Proprietary Trading Signals, it is recommended to hold off on buying at this time and monitor for a more favorable entry point.
The stock is in a bullish trend with MACD positively expanding and moving averages showing upward momentum (SMA_5 > SMA_20 > SMA_200). However, RSI at 89.391 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 85.311 and R2: 98.475, with support at S1: 42.695.
Record $41 million production order for AI chip testing, boosting investor optimism.
Analysts have upgraded the stock with higher price targets, citing strong bookings momentum and multi-year growth opportunities.
Significant investor interest in AI technologies, as reflected in increased options trading volume.
Insiders are selling heavily, with a 4388.15% increase in selling activity over the last month.
Financial performance shows a YoY revenue drop of -43.67%, and gross margin decreased by -16.77%.
Overbought technical indicators suggest the stock may face short-term resistance.
In Q3 2026, revenue dropped to $10.31M (-43.67% YoY), while net income improved to -$3.2M (+398.13% YoY). EPS increased to -0.1 (+400% YoY), but gross margin declined to 32.66% (-16.77% YoY). The financials indicate mixed results with declining revenue but improved profitability metrics.
Analysts are optimistic, with recent upgrades to Buy ratings and price targets raised to $56 and $68. They cite strong bookings momentum, AI-related growth opportunities, and multi-year revenue potential as key drivers for the stock's upside.
